188 related articles for article (PubMed ID: 34597727)
1. Emerging trends in the delivery of nanoformulated oxytocin across Blood-Brain barrier.
Al-Suhaimi EA; Nawaz M; Khan FA; Aljafary MA; Baykal A; Homeida AM
Int J Pharm; 2021 Nov; 609():121141. PubMed ID: 34597727
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle encapsulation increases the brain penetrance and duration of action of intranasal oxytocin.
Oppong-Damoah A; Zaman RU; D'Souza MJ; Murnane KS
Horm Behav; 2019 Feb; 108():20-29. PubMed ID: 30593782
[TBL] [Abstract][Full Text] [Related]
3. CSF and blood oxytocin concentration changes following intranasal delivery in macaque.
Dal Monte O; Noble PL; Turchi J; Cummins A; Averbeck BB
PLoS One; 2014; 9(8):e103677. PubMed ID: 25133536
[TBL] [Abstract][Full Text] [Related]
4. Intranasal oxytocin effects on social cognition: a critique.
Evans SL; Dal Monte O; Noble P; Averbeck BB
Brain Res; 2014 Sep; 1580():69-77. PubMed ID: 24239931
[TBL] [Abstract][Full Text] [Related]
5. Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial.
Quintana DS; Westlye LT; Alnæs D; Rustan ØG; Kaufmann T; Smerud KT; Mahmoud RA; Djupesland PG; Andreassen OA
Psychoneuroendocrinology; 2016 Jul; 69():180-8. PubMed ID: 27107209
[TBL] [Abstract][Full Text] [Related]
6. Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay.
Lee MR; Scheidweiler KB; Diao XX; Akhlaghi F; Cummins A; Huestis MA; Leggio L; Averbeck BB
Mol Psychiatry; 2018 Jan; 23(1):115-122. PubMed ID: 28289281
[TBL] [Abstract][Full Text] [Related]
7. Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies.
Bethlehem RA; van Honk J; Auyeung B; Baron-Cohen S
Psychoneuroendocrinology; 2013 Jul; 38(7):962-74. PubMed ID: 23159011
[TBL] [Abstract][Full Text] [Related]
8. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
Islam SU; Shehzad A; Ahmed MB; Lee YS
Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
[TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.
Hanson LR; Frey WH
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S5. PubMed ID: 19091002
[TBL] [Abstract][Full Text] [Related]
10. Aerosolized oxytocin increases cerebrospinal fluid oxytocin in rhesus macaques.
Modi ME; Connor-Stroud F; Landgraf R; Young LJ; Parr LA
Psychoneuroendocrinology; 2014 Jul; 45():49-57. PubMed ID: 24845176
[TBL] [Abstract][Full Text] [Related]
11. Oxytocin transported from the blood across the blood-brain barrier by receptor for advanced glycation end-products (RAGE) affects brain function related to social behavior.
Higashida H; Oshima Y; Yamamoto Y
Peptides; 2024 Aug; 178():171230. PubMed ID: 38677620
[TBL] [Abstract][Full Text] [Related]
12. A Patent Review on Nanotechnology-Based Nose-to-Brain Drug Delivery.
Singh R; Brumlik C; Vaidya M; Choudhury A
Recent Pat Nanotechnol; 2020; 14(3):174-192. PubMed ID: 32384043
[TBL] [Abstract][Full Text] [Related]
13. The effects of intranasal oxytocin on reward circuitry responses in children with autism spectrum disorder.
Greene RK; Spanos M; Alderman C; Walsh E; Bizzell J; Mosner MG; Kinard JL; Stuber GD; Chandrasekhar T; Politte LC; Sikich L; Dichter GS
J Neurodev Disord; 2018 Mar; 10(1):12. PubMed ID: 29587625
[TBL] [Abstract][Full Text] [Related]
14. Intranasal oxytocin administration is reflected in human saliva.
Weisman O; Zagoory-Sharon O; Feldman R
Psychoneuroendocrinology; 2012 Sep; 37(9):1582-6. PubMed ID: 22436536
[TBL] [Abstract][Full Text] [Related]
15. Urinary and plasma oxytocin changes in response to MDMA or intranasal oxytocin administration.
Francis SM; Kirkpatrick MG; de Wit H; Jacob S
Psychoneuroendocrinology; 2016 Dec; 74():92-100. PubMed ID: 27592327
[TBL] [Abstract][Full Text] [Related]
16. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
[TBL] [Abstract][Full Text] [Related]
17. Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics.
Kumar H; Mishra G; Sharma AK; Gothwal A; Kesharwani P; Gupta U
Pharm Nanotechnol; 2017; 5(3):203-214. PubMed ID: 28521670
[TBL] [Abstract][Full Text] [Related]
18. A Spatiotemporal Profile of In Vivo Cerebral Blood Flow Changes Following Intranasal Oxytocin in Humans.
Paloyelis Y; Doyle OM; Zelaya FO; Maltezos S; Williams SC; Fotopoulou A; Howard MA
Biol Psychiatry; 2016 Apr; 79(8):693-705. PubMed ID: 25499958
[TBL] [Abstract][Full Text] [Related]
19. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
Zhao X; Ye Y; Ge S; Sun P; Yu P
Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
[TBL] [Abstract][Full Text] [Related]
20. Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment.
Quintana DS; Westlye LT; Rustan ØG; Tesli N; Poppy CL; Smevik H; Tesli M; Røine M; Mahmoud RA; Smerud KT; Djupesland PG; Andreassen OA
Transl Psychiatry; 2015 Jul; 5(7):e602. PubMed ID: 26171983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
